share_log

Replimune Group Presented The Interim Results From The ARTACUS Clinical Trial Of RP1 Monotherapy In Solid Organ And Hematopoietic Cell Transplant Recipients With Skin Cancers At AACR 2024

レプリミューン・グループはAACR 2024で、RP1単剤療法を施した固形臓器及び造血細胞移植レシピエントの皮膚癌に関するARTACUS臨床試験の中間結果を発表しました。

Benzinga ·  04/08 02:21

In the study, treatment with RP1 as monotherapy, for up to 25 doses, resulted in an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses) with most responses ongoing as of the data cutoff date of September 18, 2023. In the evaluable patient population (n=23), 20 had cutaneous squamous cell carcinoma (CSCC) and three had merkel cell carcinoma. Of note, a patient treated with RP1 for CSCC also had a complete response of a new primary basal cell carcinoma which appeared post baseline. There was no evidence of allograft rejection including of hepatic and lung allografts. RP1 monotherapy was well tolerated, and the safety profile was similar to the profile in non-immunocompromised patients with advanced skin cancers. Additional biomarker data collected showed an increase in CD+8 T, a type of immune cell, and an increase in the expression of PD-L1, after treatment suggesting immune activation.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする